HC Wainwright Comments on Kairos Pharma Q1 Earnings

Kairos Pharma, LTD. (NYSEAMERICAN:KAPA) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Kairos Pharma in a note issued to investors on Thursday, April 3rd. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for Kairos Pharma’s Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.56) EPS and FY2028 earnings at ($0.67) EPS.

Several other brokerages have also recently commented on KAPA. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research report on Monday, March 31st. Maxim Group began coverage on shares of Kairos Pharma in a report on Thursday, March 27th. They set a “buy” rating and a $4.00 target price for the company.

Kairos Pharma Stock Performance

KAPA opened at $0.97 on Monday. The stock has a fifty day moving average price of $1.19. Kairos Pharma has a one year low of $0.85 and a one year high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.